CEO Richard Francis reflects on Teva’s return to growth during his tenure, and what’s next for the drugmaker in its quest to ...

The "Adalimumab, Infliximab, Etanercept and Trastuzumab Biosimilars Market Opportunities and Strategies to 2033" report has ...

Class A shares underperformed the MSCI ACWI ex USA Index. During the quarter, we initiated four new positions and exited one ...

Axsome Therapeutics (AXSM) is climbing nearly 4% after Swiss bank UBS increased its price target on the shares to $133 from ...

Shares of Axsome Therapeutics (NASDAQ: AXSM) are up on Tuesday. The jump comes as the S&P 500 (SNPINDEX: ^GSPC) lost 0.3% and ...

Portfolio Receipts of $742 million in Q4 2024 and $2,801 million for FY 2024Royalty Receipts growth of 12% in Q4 2024 and 13% for FY 2024 Net ...

The news caused a significant decline in the price of FTAI Aviation stock. On January 15, 2025, the price of the company's stock fell 24%, from a closing price of $153.29 per share on January 14, 2025 ...

Axsome Therapeutics, Inc.'s' stock surges 30% amid key catalysts. Learn why it's now rated a Buy wih upcoming data opportunities. Click for my AXSM update.

Camtek (Nasdaq: CAMT; TASE: CAMT) rose 2.16% for the biggest rise on the Tel Aviv 35 Index today. Nova Ltd. (Nasdaq: NVMI; TASE: NVMI) rose 1.26%, Energean plc (LSE: ENOG; TASE: ENOG) rose 1.23% and ...

Securities exhibited confidence in Axsome Therapeutics (NASDAQ:AXSM) by increasing the company's price target from $137.00 to $195.00. The firm has maintained an Outperform rating on the stock. This ...

Axsome Therapeutics (NASDAQ:AXSM) received a reiterated Buy rating and a $190.00 price target from H.C. Wainwright, representing significant upside from the current price of $127.08. The stock has ...